• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大剂量促红细胞生成素治疗急性 ST 段抬高型心肌梗死:一项随机对照试验的荟萃分析。

High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.

机构信息

Center for Translational Medicine, Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing, 210093, China.

出版信息

Am J Cardiovasc Drugs. 2013 Dec;13(6):435-42. doi: 10.1007/s40256-013-0042-3.

DOI:10.1007/s40256-013-0042-3
PMID:24097294
Abstract

OBJECTIVE

We sought to perform a meta-analysis to evaluate the potential influence of high-dose erythropoietin (EPO) on cardiac function parameters in patients with acute ST-segment elevation myocardial infarction (STEMI).

METHODS AND RESULTS

By searching PubMed, EMBASE, and the Cochrane Library (up to December 2012), seven randomized controlled trials (RCTs) reporting cardiac functional parameters with a total of 1,250 acute STEMI patients were identified. When applied to patients with acute STEMI, high-dose EPO was relatively safe and no increase in all-caused death and severe adverse effects were indicated. Estimates were pooled from fixed or random effects models. Compared with controls, high-dose EPO resulted in a slight but significant improvement in left ventricular ejection fraction of 1.02 % [95 % confidence interval (CI) 0.17-1.88, P = 0.019, I (2) = 0 %] and an improvement in left ventricular end-systolic volume of -4.61 ml (95 % CI -7.64 to -1.58, P = 0.003, I (2) = 27.7 %).

CONCLUSIONS

Available evidence suggested that high-dose EPO has limited cardio-protective effects in patients with STEMI. However, considering the relatively short follow-up durations and small patient populations in the current RCTs, the effects of high-dose EPO on clinical outcomes in patients with STEMI need to be evaluated in larger prospective RCTs of longer duration.

摘要

目的

我们旨在进行一项荟萃分析,以评估大剂量促红细胞生成素(EPO)对急性 ST 段抬高型心肌梗死(STEMI)患者心功能参数的潜在影响。

方法和结果

通过检索 PubMed、EMBASE 和 Cochrane 图书馆(截至 2012 年 12 月),我们确定了 7 项报告心功能参数的随机对照试验(RCT),共纳入 1250 例急性 STEMI 患者。在急性 STEMI 患者中应用大剂量 EPO 相对安全,并未增加全因死亡和严重不良事件。采用固定或随机效应模型进行估计。与对照组相比,大剂量 EPO 可使左心室射血分数略有但显著改善 1.02% [95%置信区间(CI)0.17-1.88,P=0.019,I (2) =0%],左心室收缩末期容积改善-4.61ml(95%CI -7.64 至-1.58,P=0.003,I (2) =27.7%)。

结论

现有证据表明,大剂量 EPO 对 STEMI 患者具有有限的心脏保护作用。然而,鉴于当前 RCT 随访时间相对较短且患者人群较小,大剂量 EPO 对 STEMI 患者临床结局的影响需要在随访时间更长的更大规模前瞻性 RCT 中进行评估。

相似文献

1
High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials.大剂量促红细胞生成素治疗急性 ST 段抬高型心肌梗死:一项随机对照试验的荟萃分析。
Am J Cardiovasc Drugs. 2013 Dec;13(6):435-42. doi: 10.1007/s40256-013-0042-3.
2
Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.ST 段抬高型心肌梗死患者再灌注后即刻给予单次高剂量促红细胞生成素治疗:促红细胞生成素治疗心肌梗死试验的结果。
Am Heart J. 2012 Feb;163(2):200-7.e1. doi: 10.1016/j.ahj.2011.11.005.
3
Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial.低剂量促红细胞生成素治疗 ST 段抬高型心肌梗死患者的设计和原理(EPO-AMI-II 研究):一项随机对照临床试验。
Cardiovasc Drugs Ther. 2012 Oct;26(5):409-16. doi: 10.1007/s10557-012-6410-4.
4
Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials.经皮冠状动脉内和内源性动员骨髓干细胞治疗 ST 段抬高型心肌梗死的短期和长期疗效:随机对照试验的荟萃分析。
Eur J Heart Fail. 2012 Jan;14(1):91-105. doi: 10.1093/eurjhf/hfr148. Epub 2011 Nov 6.
5
Low-Dose Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction (EPO-AMI-II) - A Randomized Controlled Clinical Trial.低剂量促红细胞生成素治疗 ST 段抬高型心肌梗死患者(EPO-AMI-II):一项随机对照临床试验
Circ J. 2018 Mar 23;82(4):1083-1091. doi: 10.1253/circj.CJ-17-0889. Epub 2018 Feb 2.
6
Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.促红细胞生成素治疗急性心肌梗死患者:一项随机对照试验的荟萃分析。
Am Heart J. 2012 Nov;164(5):715-727.e1. doi: 10.1016/j.ahj.2012.07.031. Epub 2012 Oct 16.
7
Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review.促红细胞生成素刺激剂对急性 ST 段抬高型心肌梗死的影响:系统评价。
Eur J Clin Pharmacol. 2012 May;68(5):469-77. doi: 10.1007/s00228-011-1160-y. Epub 2011 Nov 16.
8
Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.粒细胞集落刺激因子对心肌梗死患者左心室功能的有效性及耐受性:一项随机对照试验的荟萃分析
Clin Ther. 2007 Nov;29(11):2406-18. doi: 10.1016/j.clinthera.2007.11.008.
9
Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS).急性心肌梗死后红细胞生成素 II 期研究进展。外源性红细胞生成素在急性心肌梗死中的作用及剂量关系的研究(EPAMINONDAS)的原理和设计。
J Thromb Thrombolysis. 2009 Nov;28(4):489-95. doi: 10.1007/s11239-009-0363-x.
10
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.左心室射血分数的测量是否是细胞治疗试验的合适终点?通过心脏磁共振成像评估骨髓单个核干细胞治疗 ST 段抬高型心肌梗死后左心室射血分数的效果分析。
Am Heart J. 2011 Oct;162(4):671-7. doi: 10.1016/j.ahj.2011.06.019.

引用本文的文献

1
Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment.去唾液酸重组人促红细胞生成素作为缺血性中风治疗的潜在神经保护剂
Pharmaceuticals (Basel). 2023 Apr 18;16(4):610. doi: 10.3390/ph16040610.
2
Are There Any Cardioprotective Effects or Safety Concerns of Erythropoietin in Patients With Myocardial Infarction? A Systematic Review.促红细胞生成素对心肌梗死患者是否具有心脏保护作用或安全性问题?一项系统评价。
Cureus. 2022 Jun 5;14(6):e25671. doi: 10.7759/cureus.25671. eCollection 2022 Jun.
3
The role of PI3-K/Akt signal pathway in the antagonist effect of CEPO on CHF rats.
PI3-K/Akt信号通路在促红细胞生成素对慢性心力衰竭大鼠的拮抗作用中的作用。
Exp Ther Med. 2018 Dec;16(6):5161-5165. doi: 10.3892/etm.2018.6822. Epub 2018 Oct 2.
4
Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial.促红细胞生成素对急性心肌梗死患者的影响:REVIVAL - 3试验的五年结果
BMC Cardiovasc Disord. 2017 Jan 21;17(1):38. doi: 10.1186/s12872-016-0464-3.
5
Erythropoiesis stimulating agents and reno-protection: a meta-analysis.促红细胞生成素与肾脏保护:一项荟萃分析
BMC Nephrol. 2017 Jan 11;18(1):14. doi: 10.1186/s12882-017-0438-4.
6
Baseline Hemoglobin Levels Associated with One-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients.ST段抬高型心肌梗死患者的基线血红蛋白水平与一年死亡率的相关性
Acta Cardiol Sin. 2016 Nov;32(6):656-666. doi: 10.6515/acs20160106a.
7
Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy.促红细胞生成素与哺乳动物雷帕霉素靶蛋白:对抗与预期寿命延长相关的衰老相关疾病的“组合拳”
Curr Neurovasc Res. 2016;13(4):329-340. doi: 10.2174/1567202613666160729164900.
8
Regeneration in the nervous system with erythropoietin.促红细胞生成素在神经系统中的再生作用。
Front Biosci (Landmark Ed). 2016 Jan;21(3):561-596. doi: 10.2741/4408.
9
Erythropoietin Reduces Post-PCI Arrhythmias in Patients With ST-elevation Myocardial Infarction.促红细胞生成素可减少ST段抬高型心肌梗死患者PCI术后心律失常的发生。
J Cardiovasc Pharmacol. 2015 Jun;65(6):555-61. doi: 10.1097/FJC.0000000000000223.